Is Modified Pharmaceutical Group Marketing Co., Ltd. a subsidiary of Jilin Modified Pharmaceutical? Or other institutions? How about doing OTC in it?

Xiuzheng Pharmaceutical Group is a large-scale modern private pharmaceutical enterprise integrating scientific research, production and marketing of Chinese patent medicine, chemical medicine and biological medicine, drug chain management and standardized cultivation of Chinese herbal medicines. The Group has 35 wholly-owned subsidiaries and holding companies with more than 30,000 employees, with a total construction area of 590,000 square meters and total assets of 4.2 billion yuan. The revised pharmaceutical industry has formed a development pattern of "four groups and one station (revised pharmaceutical group, Tonghua pharmaceutical group, Changbai Mountain pharmaceutical group, health industry group and revised health website)", "two head offices (marketing head office and industry head office)" and "five centers (technology, finance, legal affairs, auditing and personnel administration)", which have been integrated in pharmaceutical enterprises in Jilin Province for seven consecutive years since 2000. "Amendment" and "Xingshu" both won the well-known trademarks in China, and they are the first pharmaceutical enterprises in China to win this honor. The network of Corrective Marketing Co., Ltd. is all over the country, and some products are exported to Southeast Asia and Europe. China famous stomach medicine brand "Starshu" has long been a household name. The national first-class new drug Weidashu, exclusive varieties of Xiangsha Ling Wei Pill, Bujin Capsule, Xiaomi Suppository, Xiaokechuan, Baoxinning, Ganshu Tablet, Xinnaokang and Yishen Anshen Oral Liquid are gradually sold at home and abroad. The revised pharmaceutical industry always follows the principle of "repairing the yuan for the benefit of the whole people"; Xiu De adheres to the corporate philosophy of "being a medicine for conscience and peace of mind" and the goal of "building a century-old revision and building a national brand". It is planned that in 20 10, the enterprise will realize the sales revenue of 10 billion, build a leading modern Chinese medicine enterprise in China, and strive to become one of the top 100 pharmaceutical enterprises in the world in 2030. At present, the state vigorously promotes the new rural cooperative medical care and community medical care. In the context of the expansion of the primary medical market by nearly 100 billion yuan, Revision Pharmaceutical established the Cardiobiliary Division at the end of 2007, based on rural hospitals and village clinics. The urban areas are dominated by community medical care, factories and mines hospitals, and large hospitals. Group companies give key support. Cardio-hepatobiliary Department has drugs for treating cardiovascular and cerebrovascular diseases (such as Baoxinning, nicotinic acid VE, Anshen Buxin Pill, etc.). ), hepatobiliary drugs (such as Liganlong, Ganshu tablets, Hugan capsules, etc.). ) and cold and cough (Xiongju Shangqing Pill, Xiaokechuan, Bujin Capsule, Maxing Zhike Tablet, etc. ) and other drugs (such as Weikangling, motherwort and Huang Min). ). The invitation letter is now widely distributed, and people with lofty ideals are cordially invited. New products, new markets and new opportunities, let's work together, unite as one, treat each other sincerely and create a brilliant life together!